Thistle Mary 4

What Happened

• Thistle Mary, a director of Cullinan Therapeutics, was granted a derivative award on 2026-06-16 representing the right to purchase 25,319 shares of the company's common stock. The Form 4 reports the acquisition price as $0.00 (the filing lists this as an award/derivative grant), so no cash purchase was reported at grant and the immediate reported value is $0.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (appears timely under the 2-business-day Form 4 rule).
• Transaction type/code: Award/derivative grant (code A).
• Shares/rights granted: Option to purchase 25,319 shares; acquisition price shown as $0.00 on the filing.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The option vests in full on the earlier of (i) June 16, 2027 or (ii) the Issuer’s next annual meeting, subject to Thistle Mary's continued service as a director on the vesting date.
• No immediate exercise or sale was reported; any future exercise or sale would generate separate Form 4 filings.

Context

• This filing documents an option grant (a derivative award) rather than an open‑market buy or sale. The grant itself does not involve cash changing hands now; value to the insider depends on future vesting and any exercise price and future stock moves.